Literature DB >> 3384986

Expression of epithelial membrane and 3-fucosyl-N-acetyllactosamine antigens in cervix uteri with particular reference to adenocarcinoma in situ.

T P Rollason1, P Byrne, A Williams, G Brown.   

Abstract

The staining patterns obtained with antiepithelial membrane antigen (anti-EMA) and the monoclonal antibody to 3-fucosyl-N-acetyllactosamine (AGF 4:48) in the uterine cervix in intraepithelial and invasive neoplasia were compared to determine a possible role in differential diagnosis of reactive and neoplastic conditions. Both early invasive and in situ adenocarcinoma stained equally intensely with both agents and both antibodies stained diffusely tubal metaplasia, endometrial lined glands, and even occasional areas of normal endocervical mucosa. It is concluded that these agents are unlikely to be of use in the routine histological differentiation of glandular and squamous cervical dysplasia or neoplasia, but immunostaining with anti-EMA may help differentiate between reactive and metaplastic changes in endocervical glands and adenocarcinoma in situ.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3384986      PMCID: PMC1141509          DOI: 10.1136/jcp.41.5.547

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Effect of neuraminidase on the expression of the 3-fucosyl-N-acetyllactosamine antigen in human tissues.

Authors:  A J Howie; G Brown
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

2.  Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens.

Authors:  T Feizi
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

3.  Stage-specific embryonic antigen involves alpha 1 goes to 3 fucosylated type 2 blood group chains.

Authors:  H C Gooi; T Feizi; A Kapadia; B B Knowles; D Solter; M J Evans
Journal:  Nature       Date:  1981-07-09       Impact factor: 49.962

4.  The value of immunohistochemical markers in the diagnosis of cervical neoplasia.

Authors:  R E Fray; O A Husain; A C To; K C Watts; S Lader; G T Rogers; J Taylor-Papadimitriou; N F Morris
Journal:  Br J Obstet Gynaecol       Date:  1984-10

5.  The morphogenesis of adenocarcinoma of the cervix-a complex pathological entity.

Authors:  M E Boon; R S Kirk; P E Rietveld-Scheffers
Journal:  Histopathology       Date:  1981-09       Impact factor: 5.087

6.  Poor prognosis in patients with adenosquamous cell carcinoma of the cervix.

Authors:  D G Gallup; R H Harper; R J Stock
Journal:  Obstet Gynecol       Date:  1985-03       Impact factor: 7.661

7.  The association between precancerous-columnar and squamous lesions of the cervix: a morphometric study.

Authors:  E van Roon; M E Boon; P J Kurver; J P Baak
Journal:  Histopathology       Date:  1983-11       Impact factor: 5.087

8.  Marker of peripheral blood granulocytes and monocytes of man recognized by two monoclonal antibodies VEP8 and VEP9 involves the trisaccharide 3-fucosyl-N-acetyllactosamine.

Authors:  H C Gooi; S J Thorpe; E F Hounsell; H Rumpold; D Kraft; O Förster; T Feizi
Journal:  Eur J Immunol       Date:  1983-04       Impact factor: 5.532

9.  Adenocarcinoma in situ of the cervix.

Authors:  A G Ostör; R Pagano; R A Davoren; D W Fortune; W Chanen; R Rome
Journal:  Int J Gynecol Pathol       Date:  1984       Impact factor: 2.762

10.  Cytoplasmic reactivity with the monoclonal antibody HMFG1 as a marker of cervical glandular atypia.

Authors:  L J Brown; N R Griffin; M Wells
Journal:  J Pathol       Date:  1987-03       Impact factor: 7.996

View more
  2 in total

1.  Nucleolar organiser regions in adenocarcinoma in situ and invasive adenocarcinoma of the cervix.

Authors:  J F Darne; S V Polacarz; E Sheridan; D Anderson; R Ginsberg; F Sharp
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

2.  Endocervical carcinoma and precursor lesions: c-myc expression and the demonstration of field changes.

Authors:  S V Polacarz; J Darne; E G Sheridan; R Ginsberg; F Sharp
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.